Pharmacokinetics of Tilmicosin (Provitil Powder and Pulmotil Liquid AC) Oral Formulations in Chickens

Overview

Journal Vet Res Commun

Publisher Springer

Specialty Veterinary Medicine

Date 2007 Jan 17

PMID 17225089

Citations 8

Authors

E A Abu-Basha

N M Idkaidek

A F Al-Shunnaq

Affiliations

Soon will be listed here.

Abstract

A bioavailability and pharmacokinetics study of powder and liquid tilmicosin formulations was carried out in 18 healthy chickens according to a single-dose, two-period, two-sequence, crossover randomized design. The two formulations were Provitil and Pulmotil AC. Both drugs were administered to each chicken after an overnight fast on two treatment days separated by a 2-week washout period. A modified rapid and sensitive HPLC method was used for determination of tilmicosin concentrations in chicken plasma. Various pharmacokinetic parameters including area under plasma concentration-time curve (AUC(0-72)), maximum plasma concentration (C(max)), time to peak concentration (t(max)), elimination half-life (t(1/2beta)), elimination rate (k(el)), clearance (Cl(B)), mean residence time (MRT) and volume of distribution (V(d,area)) were determined for both formulations. The average means of AUC(0-72) for Provitil and Pulmotil AC were very close (24.24 +/- 3.86, 21.82 +/- 3.14 (microg x h)/ml, respectively), with no significant differences based on ANOVA. The relative bioavailability of Provitil as compared to Pulmotil AC was 111%. In addition, there were no significant differences in the C(max) (2.09 +/- 0.37, 2.12 +/- 0.40 microg/ml), tmax (3.99 +/- 0.84, 5.82 +/- 1.04 h), t(1/2beta) (47.4 +/- 9.32, 45.0 +/- 5.73 h), k(el) (0.021 +/- 0.0037, 0.022 +/- 0.0038 h(-1)), Cl(B) (19.73 +/- 3.73, 21.37 +/- 4.54ml/(min/kg)), MRT (71.20 +/- 12.87, 67.15 +/- 9.01 h) and V(d,area) (1024.8 +/- 87.5, 1009.8 +/- 79.5 ml/kg) between Pulmotil AC and Provitil, respectively. In conclusion, tilmicosin was rapidly absorbed and slowly eliminated after oral administration of single dose of tilmicosin aqueous and powder formulations. Provitil and Pulmotil AC can be used as interchangeable therapeutic agents.

Citing Articles

The Monitoring of Minimum Inhibitory Concentrations during the Last Decade (2010-2020) Seems to Reveal a Comeback of Susceptibility to Macrolides, Tiamulin, and Lincomycin.

Bottinelli M, Gastaldelli M, Picchi M, DallOra A, Cristovao Borges L, Ramirez A Antibiotics (Basel). 2022; 11(8).

PMID: 36009890 PMC: 9404793. DOI: 10.3390/antibiotics11081021.

and Resistance Analysis of Tilmicosin Against in an Dynamic Model.

Huang Z, Wu Y, Zhou Z, Xia X, Gu X, Cai Q Front Pharmacol. 2019; 10:670.

PMID: 31293418 PMC: 6598723. DOI: 10.3389/fphar.2019.00670.

Quick Multi-Class Determination of Residues of Antimicrobial Veterinary Drugs in Animal Muscle by LC-MS/MS.

Zhang M, Li E, Su Y, Zhang Y, Xie J, He L Molecules. 2018; 23(7).

PMID: 30012996 PMC: 6099539. DOI: 10.3390/molecules23071736.

Determination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and Valnemulin.

Zhang N, Ye X, Wu Y, Huang Z, Gu X, Cai Q PLoS One. 2017; 12(1):e0169134.

PMID: 28052123 PMC: 5215565. DOI: 10.1371/journal.pone.0169134.

The Epidemiologic and Pharmacodynamic Cutoff Values of Tilmicosin against Haemophilus parasuis.

Zhang P, Hao H, Li J, Ahmad I, Cheng G, Chen D Front Microbiol. 2016; 7:385.

PMID: 27047487 PMC: 4802331. DOI: 10.3389/fmicb.2016.00385.

References

Jordan F, Horrocks B . The minimum inhibitory concentration of tilmicosin and tylosin for mycoplasma gallisepticum and Mycoplasma synoviae and a comparison of their efficacy in the control of Mycoplasma gallisepticum infection in broiler chicks. Avian Dis. 1996; 40(2):326-34. View

Toutain P, Bousquet-Melou A . Bioavailability and its assessment. J Vet Pharmacol Ther. 2004; 27(6):455-66. DOI: 10.1111/j.1365-2885.2004.00604.x. View

Modric S, Webb A, Davidson M . Effect of respiratory tract disease on pharmacokinetics of tilmicosin in rats. Lab Anim Sci. 1999; 49(3):248-53. View

Ramadan A . Pharmacokinetics of tilmicosin in serum and milk of goats. Res Vet Sci. 1997; 62(1):48-50. DOI: 10.1016/s0034-5288(97)90179-x. View

Salmon S, Watts J, Case C, Hoffman L, Wegener H, Yancey Jr R . Comparison of MICs of ceftiofur and other antimicrobial agents against bacterial pathogens of swine from the United States, Canada, and Denmark. J Clin Microbiol. 1995; 33(9):2435-44. PMC: 228432. DOI: 10.1128/jcm.33.9.2435-2444.1995. View

Kempf I, Reeve-Johnson L, Gesbert F, Guittet M . Efficacy of tilmicosin in the control of experimental Mycoplasma gallisepticum infection in chickens. Avian Dis. 1998; 41(4):802-7. View

Shen J, Li C, Jiang H, Zhang S, Guo P, Ding S . Pharmacokinetics of tilmicosin after oral administration in swine. Am J Vet Res. 2005; 66(6):1071-4. DOI: 10.2460/ajvr.2005.66.1071. View

Chen M, Shah V, Patnaik R, Adams W, Hussain A, Conner D . Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res. 2002; 18(12):1645-50. DOI: 10.1023/a:1013319408893. View

Vogel G, Laudert S, Zimmermann A, Guthrie C, Mechor G, Moore G . Effects of tilmicosin on acute undifferentiated respiratory tract disease in newly arrived feedlot cattle. J Am Vet Med Assoc. 1998; 212(12):1919-24. View

10.

JORDAN W, Byrd R, COCHRANE R, Hanasono G, Hoyt J, MAIN B . A review of the toxicology of the antibiotic MICOTIL 300. Vet Hum Toxicol. 1993; 35(2):151-8. View

11.

Blackall P, Asakawa T, Graydon R, White M, Adamson M, Wade L . In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs. Aust Vet J. 1995; 72(1):35-6. DOI: 10.1111/j.1751-0813.1995.tb03475.x. View

12.

Moore G, Basson R, Tonkinson L . Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine. Am J Vet Res. 1996; 57(2):224-8. View

13.

MAIN B, Means J, Rinkema L, Smith W, Sarazan R . Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine, in conscious unrestrained dogs. J Vet Pharmacol Ther. 1996; 19(3):225-32. DOI: 10.1111/j.1365-2885.1996.tb00042.x. View

14.

Watkins K, Shryock T, Dearth R, Saif Y . In-vitro antimicrobial susceptibility of Clostridium perfringens from commercial turkey and broiler chicken origin. Vet Microbiol. 1997; 54(2):195-200. DOI: 10.1016/s0378-1135(96)01276-x. View

15.

Scorneaux B, Shryock T . Intracellular accumulation, subcellular distribution, and efflux of tilmicosin in bovine mammary, blood, and lung cells. J Dairy Sci. 1999; 82(6):1202-12. DOI: 10.3168/jds.S0022-0302(99)75343-9. View

16.

Hoar B, Jelinski M, Ribble C, Janzen E, Johnson J . A comparison of the clinical field efficacy and safety of florfenicol and tilmicosin for the treatment of undifferentiated bovine respiratory disease of cattle in western Canada. Can Vet J. 1998; 39(3):161-6. PMC: 1539941. View

17.

Anger B, Laurentie M . Multiresidue chromatographic method for the determination of macrolide residues in muscle by high-performance liquid chromatography with UV detection. J AOAC Int. 1999; 82(5):1046-53. View

18.

Modric S, Webb A, Derendorf H . Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. J Vet Pharmacol Ther. 1999; 21(6):444-52. DOI: 10.1046/j.1365-2885.1998.00177.x. View

19.

Christodoulopoulos G, Warnick L, Papaioannou N, Fthenakis G . Tilmicosin administration to young lambs with respiratory infection: safety and efficacy considerations. J Vet Pharmacol Ther. 2002; 25(5):393-7. DOI: 10.1046/j.1365-2885.2002.00433.x. View

20.

Varga J, Fodor L, Makrai L . Characterisation of some Ornithobacterium rhinotracheale strains and examination of their transmission via eggs. Acta Vet Hung. 2001; 49(2):125-30. DOI: 10.1556/004.49.2001.2.1. View